CODA Biotherapeutics acquires Attenua

5 February 2020
coda_large

California, USA-based clinical-stage biotech CODA Biotherapeutics today announced it has completed the acquisition of Attenua. Financial terms of the transaction are not being disclosed.

With the acquisition, CODA has obtained three small-molecule drugs that have been shown to be safe and well tolerated in multiple clinical trials up to and including Phase II studies. CODA has engineered several chemogenetic receptors that can be specifically controlled by small molecule ligands, including clinical stage candidates from the Attenua portfolio. CODA plans to evaluate and advance these unique receptor-ligand pairs toward the clinic to treat neuropathic pain, focal epilepsy, and other neurologic diseases and disorders.

"We are fortunate to be able to acquire these three small-molecule therapeutics that have a tremendous amount of high-quality drug development work already completed, one with a currently active IND. Prior to the acquisition, our team has engineered several chemogenetic ion channel receptors that can be specifically controlled by these clinical stage drugs. The robust data packages accompanying these assets will decrease time, cost, and risks as we move toward human clinical trials where we hope to demonstrate transformative results for patients," said Michael Narachi, president and chief executive of CODA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology